NCT01193699View on ClinicalTrials.gov

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 25, 2018

Study Completion Date

January 25, 2018

Conditions
Polycythemia Vera
Interventions
DRUG

PEG-P-INF alpha-2b (P1101)

µg (starting with 50 µg), subcutaneously, 2-weekly administration

Trial Locations (6)

1090

Vienna

1140

Vienna

1220

Vienna

4600

Wels

5020

Salzburg

6020

Innsbruck

Sponsors
All Listed Sponsors
lead

AOP Orphan Pharmaceuticals AG

INDUSTRY

NCT01193699 - Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera | Biotech Hunter | Biotech Hunter